Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation

British Journal of Haematology

Volumn 141, Issue 1, 2008, Pages 80-83

  Ciurea, Stefan O ^b   Sadegi, Barry ^b   Wilbur, Andrew ^b   Alagiozian Angelova, Victoria ^b   Gaitonde, Sujata ^b   Dobogai, Lisa C ^b   Akard, Luke P ^c   Hoffman, Ronald ^d,e   Rondelli, Damiano ^a,b,e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c Indiana Blood and Marrow Transplantation   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e Myeloproliferative Diseases Research Consortium

Author keywords

Myelofibrosis; Myeloproliferative disorder; Reduced intensity conditioning stem cell transplantation; Splenomegaly

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; CLADRIBINE; CYCLOSPORIN; FLUDARABINE; HYDROXYUREA; MELPHALAN; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MYELOFIBROSIS; NEUTROPHIL; PRIORITY JOURNAL; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTE;

FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; MYELOFIBROSIS; PLATELET COUNT; PROGNOSIS; RETROSPECTIVE STUDIES; SPLENOMEGALY; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 40449131772     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07010.x     Document Type: Article

References (12)

1. Barosi, G., Ambrosetti, A., Finelli, C., Grossi, A., Leoni, P., Liberato, N.L., Petti, M.C., Pogliani, E., Ricetti, M., Rupoli, S., Visani, G. Tura, S. (1999) The Italian Consensus Conference of Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. British Journal of Haematology, 104, 730 737.
2. Bezerra, A.S., D'Ippolito, G., Faintuch, A., Szejnfeld, J. Ahmed, M. (2005) Determination of splenomegaly by CT: is there a place for a single measurement? American Journal of Roentgenology, 184, 1510 1513.
3. Byrne, J.L., Beshti, H., Clark, D., Ellis, I., Haynes, A.P., Das-Gupta, E. Russell, N.H. (2000) Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect. British Journal of Haematology, 108, 430 433.
4. Dupriez, B., Morel, P., Demory, J.L., Lai, J.L., Simon, M., Plantier, I. Bauters, F. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 1013 1018.
5. Hoffman, R., Prchal, J.T., Samuelson, S., Ciurea, S.O. Rondelli, D. (2007) Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment. Biology of Blood and Marrow Transplant, 13, 64 72.
6. Kroger, N., Zabelina, T., Schieder, H., Panse, J., Ayuk, F., Stute, N., Fehse, N., Waschke, O., Fehse, B., Kvasnicka, H.M., Thiele, J. Zander, A. (2005) Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation for related and unrelated donors in patients with myelofibrosis. British Journal of Haematology, 128, 690 697.
7. Li, Z., Gooley, T., Appelbaum, F.R. Deeg, J. (2001) Splenectomy and hematopoietic stem cell transplantation for myelofibrosis. Blood, 97, 2180 2181.
8. Mesa, R.A., Nagorney, D.S., Schwager, S., Allred, J. Tefferi, A. (2006) Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer, 107, 361 370.
9. Ni, H., Barosi, G., Rondelli, D. Hoffman, R. (2005) Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis. American Journal of Clinical Pathology, 123, 833 839.
10. Rondelli, D., Barosi, G., Bacigalupo, A., Prchal, J.T., Popat, U., Alessandrino, E.P., Spivak, J.L., Smith, B.D., Klingemann, H.G., Fruchtman, S. Hoffman, R. (2005) Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood, 105, 4115 4119.
11. Tefferi, A., Barosi, G., Mesa, R., Cervantes, F., Deeg, H.J., Reilly, J.T., Verstovsek, S., Dupriez, B., Silver, R.T., Odenike, O., Cortes, J., Wadleigh, M., Solberg Jr. L.A., Camoriano, J.K., Gisslinger, H., Noel, P., Thiele, J., Vardiman, J.W., Hoffman, R., Cross, N.C., Gilliland, D.G. Kantarjian, H. & IWG for Myelofibrosis Research and Treatment (IWG-MRT) (2006) International working group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT). Blood, 108, 1497 1503.
12. Yetter, E.M., Acosta, K.B., Olson, M.C. Blundell, K. (2003) Estimating splenic volume: sonographic measurments correlated with helical CT determination. American Journal of Roentgenology, 181, 1615 1620.